Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Traci McCarty - Vice President, Investor Relations J.J. Bienaime - Chairman and Chief Executive Officer Jeff Ajer - Executive Vice President and Chief Commercial Officer Hank Fuchs - President, Worldwide Research and Development Greg Guyer - Executive Vice President and Chief Technical Officer Brian Mueller - Executive Vice President and Chief Financial Officer Conference Call Participa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________ Form 10-K ____________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 ____________ BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) D ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2021 Results Conference Call February 23, 2022 4:30 PM ET Company Participants Traci McCarty - Vice President of Investor Relations J.J. Bienaime - Chairman and Chief Executive Officer Jeff Ajer - Executive Vice President and Chief Commercial Officer Hank Fuchs - President, Worldwide Research and Development Greg Guyer - Executive Vice President and Chief Technical Officer Brian Mueller - Executive Vice President, Chief Financial Officer Conference Call Particip ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2021 Earnings Conference Call October 28, 2021 4:30 PM ET Company Participants J.J. Bienaime – Chairman and Chief Executive Officer Traci Mc Carty – Vice President of Investor Relations Jeff Ajer – Executive Vice President and Chief Commercial Officer Hank Fuchs – President worldwide research and development Reg Guyer – Executive Vice President Chief Financial Officer Brian Mueller – Executive Vice President, Chief Financial Officer Conference Call Participants ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2021 Results Conference Call July 28, 2021 4:30 PM ET Company Participants Traci McCarty - VP, IR J.J. Bienaimé - Chairman and CEO Jeff Ajer - EVP and Chief Commercial Officer Hank Fuchs - President, Worldwide Research and Development Greg Guyer - EVP and Chief Technical Officer Brian Mueller - EVP and CFO Conference Call Participants Cory Kasimov - JP Morgan Robyn Karnauskas - Truist Securities Salveen Richter - Goldman Sachs Geoff Meacham - Bank of America Deb ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . | --- | --- | --- | |------------------------------------ ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2021 Results Conference Call April 29, 2021 4:30 PM ET Company Participants | --- | |----------------------------------------------| | | | | | Traci McCarty - VP, IR | | J.J. Bienaime - Chairman and CEO | | Jeff Ajer - EVP and Chief Commercial Officer | | Hank Fuchs - President, Worldwide R&D | | Greg Guyer - EVP and Chief Technical Officer | | Brian Mueller - EVP and CFO | | Conference Call Participants | | Joori Park - SVB Leerink | | Chris Raymond - Piper San ...